Diabetic patients suffering diabetic foot ulcers (wounds) are benefiting from pioneering efforts in wound therapy. Tissue Regenix, an international medical technology company is leading the development of a range of regenerative products to make specialized replacement tissue using biological (human & animal) materials. The company offers an expanding roster of products based on their patented dCELL® decellularization technology to provide acellular tissue scaffolds which are not rejected by the patient's body. DermaPure® is a new decellularized human dermis product from Tissue Regenix used by physicians to help promote wound healing. Initial clinical use has demonstrated that DermaPure® allografts may have scaffold characteristics - including elasticity, porosity and bio-compatibility - comparable to natural tissue, which have been shown to promote beneficial cellular activity during healing.
